P
Priya Prakash Karmali
Researcher at Sanford-Burnham Institute for Medical Research
Publications - 28
Citations - 4024
Priya Prakash Karmali is an academic researcher from Sanford-Burnham Institute for Medical Research. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 16, co-authored 20 publications receiving 3562 citations. Previous affiliations of Priya Prakash Karmali include University of California, Santa Barbara.
Papers
More filters
Journal ArticleDOI
Tissue-penetrating delivery of compounds and nanoparticles into tumors
Kazuki N. Sugahara,Tambet Teesalu,Priya Prakash Karmali,Venkata Ramana Kotamraju,Lilach Agemy,Olivier M. Girard,Douglas Hanahan,Robert F. Mattrey,Erkki Ruoslahti,Erkki Ruoslahti +9 more
TL;DR: Conjugation to iRGD significantly improved the sensitivity of tumor-imaging agents and enhanced the activity of an antitumor drug.
Journal ArticleDOI
Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.
Kazuki N. Sugahara,Tambet Teesalu,Priya Prakash Karmali,Venkata Ramana Kotamraju,Lilach Agemy,Daniel R. Greenwald,Erkki Ruoslahti,Erkki Ruoslahti +7 more
TL;DR: Mouse tumor models show that coinjection of the iRGD peptide increases the tumor penetration and antitumor activity of several cancer drugs, including the cytotoxic agent doxorubicin and the therapeutic antibody trastuzumab (Herceptin), without increasing their harmful effects on healthy tissue.
Journal ArticleDOI
Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems.
TL;DR: The immune recognition of nanoparticles can seriously affect the drug delivery efficacy and toxicity, and there is at present not enough knowledge on the mechanisms that dictate the nanoparticle immune recognition and stability in the biological milieu.
Journal ArticleDOI
Mitochondrial p32 Protein Is a Critical Regulator of Tumor Metabolism via Maintenance of Oxidative Phosphorylation
Valentina Fogal,Adam D. Richardson,Priya Prakash Karmali,Immo E. Scheffler,Jeffrey W. Smith,Erkki Ruoslahti,Erkki Ruoslahti +6 more
TL;DR: It is shown that knocking down p32 expression in human cancer cells strongly shifts their metabolism from oxidative phosphorylation (OXPHOS) to glycolysis, and suggests that tumor cells use p32 to regulate the balance between OXPHOS and gly colysis.
Journal ArticleDOI
Targeting atherosclerosis by using modular, multifunctional micelles
David Peters,Mark Kastantin,Venkata Ramana Kotamraju,Priya Prakash Karmali,Kunal Gujraty,Matthew Tirrell,Erkki Ruoslahti,Erkki Ruoslahti +7 more
TL;DR: Modular multifunctional micelles that contain a targeting element, a fluorophore, and, when desired, a drug component in the same particle are developed that target subtle clotting that occurs on the luminal surface of atherosclerotic plaques.